Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits) DOI Creative Commons

Susanne Bejerot,

Daniel Eklund, Hugo Hesser

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 6, 2023

Abstract Background: The role of inflammation in the aetiology schizophrenia has gained wide attention and research on association shows an exponential growth last 15 years. Autoimmune diseases severe infections are risk factors for later development schizophrenia, elevated inflammatory markers childhood or adolescence associated with a greater adulthood, individuals have increased levels pro-inflammatory cytokines compared to healthy controls, autoimmune overrepresented schizophrenia. However, treatments anti-inflammatory agents so far doubtful clinical relevance. primary objective this study is test whether monoclonal antibody rituximab, directed against B-cell antigen CD20 ameliorates psychotic symptoms adults schizoaffective disorder examine potential mechanisms. A secondary characteristics inflammation-associated psychosis identify pre-treatment biochemical rituximab responders. third interview subset patients informants their experiences trial obtain insights that rating scales may not capture. Methods: proof-of-concept employing randomised, parallel-group, double-blind, placebo-controlled design testing effect depletion psychosis. 120 participants diagnosis spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion (1000 mg) saline. Psychiatric measures blood samples be collected at baseline, week 12, 24 post-infusion. Brief assessments also made weeks 2 7. Neuroimaging lumbar puncture, both optional, performed baseline endpoints. Approximately 40 interviewed qualitative analyses perceived changes well-being emotional qualities, addition views research. Discussion: This first RCT investigating add-on treatment unselected SSD patients. If helpful, it transform disorders. It heighten awareness immune-psychiatric reduce stigma. Trial registration: NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14 th October 2022.

Language: Английский

Obsessive-Compulsive Disorder DOI Open Access

Hassan I. Osman

International Journal of Research Publications, Journal Year: 2024, Volume and Issue: 50(1)

Published: May 16, 2024

Introduction: Obsessive-Compulsive Disorder is a highly-disabling mental illness that results in the suffering of many individuals around world. In this article, disorder fully looked into: how it occurs, its pathophysiology, treatment, and suggested future advances management study disorder. Research Methodology: A number search engines (Google Scholar, PubMed, google.com, etc.) were searched with aforementioned keywords. This resulted plethora results. These were, turn, filtered through known criteria regarding their eligibility for usage review articles. Some sources inaccessible ergo, excluded from being used here. Moreover, other found to be published predatory journals. Duplicate findings course, eliminated. Fol lowing this, based on relevance topic article. The data included here was revised eligible use then, only they

Language: Английский

Citations

0
Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia DOI
Marta Iglesias‐Martínez‐Almeida,

Ana Campos-Ríos,

Luis Freiría-Martínez

et al.

Schizophrenia Research, Journal Year: 2024, Volume and Issue: 270, P. 260 - 272

Published: June 29, 2024

Language: Английский

Citations

0
Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits) DOI Creative Commons

Susanne Bejerot,

Daniel Eklund, Hugo Hesser

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 6, 2023

Abstract Background: The role of inflammation in the aetiology schizophrenia has gained wide attention and research on association shows an exponential growth last 15 years. Autoimmune diseases severe infections are risk factors for later development schizophrenia, elevated inflammatory markers childhood or adolescence associated with a greater adulthood, individuals have increased levels pro-inflammatory cytokines compared to healthy controls, autoimmune overrepresented schizophrenia. However, treatments anti-inflammatory agents so far doubtful clinical relevance. primary objective this study is test whether monoclonal antibody rituximab, directed against B-cell antigen CD20 ameliorates psychotic symptoms adults schizoaffective disorder examine potential mechanisms. A secondary characteristics inflammation-associated psychosis identify pre-treatment biochemical rituximab responders. third interview subset patients informants their experiences trial obtain insights that rating scales may not capture. Methods: proof-of-concept employing randomised, parallel-group, double-blind, placebo-controlled design testing effect depletion psychosis. 120 participants diagnosis spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion (1000 mg) saline. Psychiatric measures blood samples be collected at baseline, week 12, 24 post-infusion. Brief assessments also made weeks 2 7. Neuroimaging lumbar puncture, both optional, performed baseline endpoints. Approximately 40 interviewed qualitative analyses perceived changes well-being emotional qualities, addition views research. Discussion: This first RCT investigating add-on treatment unselected SSD patients. If helpful, it transform disorders. It heighten awareness immune-psychiatric reduce stigma. Trial registration: NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14 th October 2022.

Language: Английский

Citations

0